Alfredo Lee Chang, MD
Critical Care Medicine · Los Angeles, CANPI 1689944407
Payments from drug & device makers
Across 195 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$943
- Boehringer Ingelheim$601
- Merck$332
- Actelion Pharmaceuticals US, Inc.$326
- Sanofi$298
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,442100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $1,756 |
| AstraZeneca | 23 | $943 |
| Boehringer Ingelheim | 27 | $601 |
| Merck | 9 | $332 |
| Actelion Pharmaceuticals US, Inc. | 8 | $326 |
| Sanofi | 8 | $298 |
| Regeneron Healthcare Solutions, Inc. | 3 | $171 |
| Verona Pharma, Inc. | 6 | $143 |
| Mylan Specialty L.p. | 7 | $134 |
| Intuitive Surgical | 1 | $132 |
| Electromed, Inc. | 8 | $97 |
| United Therapeutics Corporation | 3 | $88 |
| Viatris Specialty LLC | 4 | $84 |
| Shionogi Inc | 2 | $53 |
| Harmony Biosciences LLC | 1 | $49 |
| Pulmonx Corporation | 2 | $44 |
| Baxter Healthcare | 2 | $38 |
| Philips North America LLC | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$500
- NUCALA$372
- DUPIXENT$223
- Da Vinci Surgical System$132
- UPTRAVI$125
- OPSUMIT$125
- WINREVAIR$122
- TRELEGY ELLIPTA$107
- FASENRA$102
How this compares
$5,442 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 599 | $381,223 |
| OfevNintedanib Esylate | 22 | $285,157 |
| NucalaMepolizumab | 27 | $110,425 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $50,315 |
| Breo ElliptaFluticasone/Vilanterol | 123 | $46,700 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 82 | $46,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $35,873 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 53 | $28,933 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 607 | $19,641 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 36 | $16,426 |
| Bosentan | 12 | $14,935 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $12,626 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 63 | $9,537 |
| EliquisApixaban | 18 | $9,127 |
| Atrovent HfaIpratropium Bromide | 16 | $7,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,756 | $601,288885 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat | $601 | $360,638157 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Daliresp | $943 | $57,056104 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $326 | $14,93512 claims |
| Johnson & JohnsonInvokana | $22 | $6,27111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Los Angeles
- Alex HakimLos Angeles$946K
- Adupa RaoLos Angeles$274K
- Tisha WangLos Angeles$231K
- Luis HuertaLos Angeles$61K
- Christopher NewthLos Angeles$37K
- Santhi KumarLos Angeles$28K
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.